ARTICLE | Regulation
Panel set for trio of COVID vaccines
Plus EMA reviewing GSK, Sanofi’s Vidprevtyn and updates from Novartis and more
April 30, 2022 1:20 AM UTC
FDA’s Vaccines and Related Biological Products Advisory Committee will meet over four days to discuss EUAs for three different vaccines.
June 7, the committee will discuss NVX-CoV2373 from Novavax Inc. (NASDAQ:NVAX), the EUA for which the company submitted on Jan. 31. Developed in collaboration with the Coalition for Epidemic Preparedness Innovations and partially funded by Operation Warp Speed, NVX-CoV2373, also known as Covovax, is a recombinant protein nanoparticle vaccine against a full-length, pre-fusion stabilized version of the SARS-CoV-2 spike protein, delivered in combination with the company’s saponin-based Matrix-M adjuvant. ...